References
- 1. Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med. 2003;17: 136-144.
- 2. Knapp DW, Ramos-Vara JA, Moore GE, Dhawan D, Bonney PL, Young KE. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J. 2014;55: 100-118.
- 3. Raghavan M, Knapp DW, Bonney PL, Dawson MH, Glickman LT. Evaluation of the effect of dietary vegetable consumption on reducing risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. J Am Vet Med Assoc. 2005;227: 94-100.
- 4. Raghavan M, Knapp DW, Dawson MH, Bonney PL, Glickman LT. Topical fl ea and tick pesticides and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. J Am Vet Med Assoc. 2004;225: 389-394.
- 5. Glickman LT, Raghavan M, Knapp DW, Bonney PL, Dawson MH. Herbicide exposure and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. J Am Vet Med Assoc. 2004;224: 1290-1297.
- 6. Withrow SJ, Vail DM, Page RL. Small Animal Clinical Oncology. In: Knapp DW, McMillan SK, editors. Tumors of the urinary System: Elsevier, 2013.
- 7. Knapp DW, Glickman NW, Denicola DB, Bonney PL, Lin TL, Glickman LT. Naturallyoccurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer. Urol Oncol. 2000;5: 47-59.
- 8. Valli VE, Norris A, Jacobs RM, Laing E, Withrow S, Macy D, Tomlinson J, McCaw D, Ogilvie GK, Pidgeon G, Henderson RA. Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival. J Comp Pathol. 1995;113: 113-130.
- 9. L.N. O. TNM Classifi cation of Tumors in Domestic Animals. In: WHO, editor. Geneva: World Health Organization (WHO), 1980.
- 10. Fulkerson CM, Knapp DW. Management of transitional cell carcinoma of the urinary bladder in dogs: a review. Vet J. 2015;205: 217-225.
- 11. Knapp DW, Henry CJ, Widmer WR, Tan KM, Moore GE, Ramos-Vara JA, Lucroy MD, Greenberg CB, Greene SN, Abbo AH, Hanson PD, Alva R, Bonney PL. Randomized trial of cisplatin versus fi rocoxib versus cisplatin/fi rocoxib in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 2013;27: 126-133.
- 12. Cannon CM, Allstadt SD. Lower urinary tract cancer. Vet Clin North Am Small Anim Pract. 2015;45: 807-824.
- 13. Morales A, Cohen Z. Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin. Expert Opin Biol Ther. 2016;16: 273-283.
- 14. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol. 2009;181: 1040-1045.
- 15. Morales A. Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent. Expert Opin Investig Drugs. 2008;17: 1067-1073.
- 16. Morales A, Chin JL, Ramsey EW. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol. 2001;166: 1633-1637; discussion 1637-1638.
- 17. Chin JL, Kadhim SA, Batislam E, Karlik SJ, Garcia BM, Nickel JC, Morales A. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol. 1996;156: 1189-1193.
- 18. Alkemade. SJ, Buckley TC, McRae. G. Immunostimulatory bacterial cell wall fraction. In: USPTO, editor. Unated States of America: Vetrepharm, Inc, 1998.
- 19. Filion MC, Phillips NC. Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin Investig Drugs. 2001;10: 2157-2165.
- 20. Rodrigues L, Masic A. Mycobacterium Cell Wall Fraction (Immunocidin®) for Canine Transitional Cell Carcinoma Treatment. Veterinary Cancer Society Conference 2015. Tysons, VA, 2015:29.
- 21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65: 55-63.
- 22. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2011.
- 23. McMillan SK, Boria P, Moore GE, Widmer WR, Bonney PL, Knapp DW. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc. 2011;239: 1084-1089.
- 24. Lynch S, Savary-Bataille K, Leeuw B, Argyle DJ. Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Comp Oncol. 2011;9: 172-182.
- 25. Naughton JF, Widmer WR, Constable PD, Knapp DW. Accuracy of three-dimensional and two-dimensional ultrasonography for measurement of tumor volume in dogs with transitional cell carcinoma of the urinary bladder. Am J Vet Res. 2012;73: 1919-1924.
- 26. Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol. 2013.
- 27. D. W. Knapp BF, M. C. Filion and N. C. Phillips. Antitumor activity of mycobacterial cell wall-DNA complex (MCC) against canine urinary bladder transitional cell carcinoma cells. Veterinary Cancer Society Annual Conference Kansas City. Kansas City Missouri, , : Blackwell Publishing Ltd, 2004:46-47.
- 28. Azuma I, Taniyama T, Hirao F, Yamamura Y. Antitumor activity of cell-wall skeletons and peptidoglycolipids of mycobacteria and related microorganisms in mice and rabbits. Gan. 1974;65: 493-505.
- 29. Filion MC, Lepicier P, Morales A, Phillips NC. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br J Cancer. 1999;79: 229-235.
- 30. Fumuso EA, Aguilar J, Giguere S, Rivulgo M, Wade J, Rogan D. Immune parameters in mares resistant and susceptible to persistent post-breeding endometritis: effects of immunomodulation. Vet Immunol Immunopathol. 2007;118: 30-39.
- 31. Reader S, Menard S, Filion B, Filion MC, Phillips NC. Pro-apoptotic and immunomodulatory activity of a mycobacterial cell wall-DNA complex towards LNCaP prostate cancer cells. Prostate. 2001;49: 155-165.
- 32. Yamanaka K, Hara I, Nagai H, Miyake H, Gohji K, Micallef MJ, Kurimoto M, Arakawa S, Kamidono S. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother. 1999;48: 297-302.
- 33. Filion MC, Filion B, Reader S, Menard S, Phillips NC. Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex. Cancer Immunol Immunother. 2000;49: 325-334.
- 34. Knapp DW, Richardson RC, Chan TC, Bottoms GD, Widmer WR, DeNicola DB, Teclaw R, Bonney PL, Kuczek T. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med. 1994;8: 273-278.